Comparative Pharmacology
Head-to-head clinical analysis: DELTA DOME versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTA DOME versus KENALOG IN ORABASE.
DELTA-DOME vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Delta-dome agents, likely referring to delta-9-tetrahydrocannabinol (THC) analogs or synthetic cannabinoids, act as partial agonists at cannabinoid receptors CB1 and CB2. CB1 receptors are primarily located in the central nervous system, modulating neurotransmitter release, while CB2 receptors are mainly in immune cells, influencing cytokine release and immune response.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Intramuscular or subcutaneous injection of 0.5 to 1 mL (5-10 mg/mL) every 4 to 6 hours as needed.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in adults, prolonged to 4-8 hours in hepatic impairment; correlates with duration of pulmonary effects.
Terminal half-life approximately 2-5 hours following mucosal application.
Primarily hepatic metabolism with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces as bile salts). Less than 1% excreted unchanged.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid